Sarepta's Duchenne gene therapy misses main goal in study-March 2024-www.financetom.com

Sarepta's Duchenne gene therapy misses main goal in study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025 1:36 PM

Nov 3 (Reuters) - Sarepta said on Monday that

its late-stage study testing two gene-targeted therapies for

Duchenne muscular dystrophy did not meet the main goal.

Previous page： Elon Musk Faces Deadline To Settle With SEC Over Twitter Buyout: Lawyer Alleges 'Years Of Harassment' Next page： Know Labs Prices $300,000 Registered Direct Offering

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Elon Musk Faces Deadline To Settle With SEC Over Twitter Buyout: Lawyer Alleges 'Years Of Harassment'

Dec 13, 2024

Billionaire Elon Musk is facing a deadline to respond to an offer to resolve a SEC case over his buyout of Twitter, now known as X, which he bought for $44 billion in 2022. What Happened: Musk recently shared a letter his lawyer Alex Spiro sent to the SEC over a reported 48-hour deadline to respond to an offer to...

Know Labs Prices $300,000 Registered Direct Offering

Dec 13, 2024

12:01 PM EST, 12/13/2024 (MT Newswires) -- Know Labs ( KNW ) said Friday it priced a registered direct offering of units for gross proceeds of $300,000. The company said the purchase price of the unit, which comprises one share of stock and one warrant, was $0.24 a share, with the warrant exercisable at $0.24. Shares of Know Labs (...

Rio Tinto Explores Gallium Extraction From Alumina Refinery in Canada

Dec 13, 2024

12:01 PM EST, 12/13/2024 (MT Newswires) -- Rio Tinto (RIO) said Friday it is exploring the possibility of extracting and valorising gallium from its Canadian alumina refinery. Following initial testing, the company plans to build a demonstration plant, supported by up to CA$7 million ($4.92 million) in funding from the Quebec government, to produce up to 3.5 tonnes of gallium...

Eaton Poised for Strong Growth With Robust Backlog, Longer Order Lead Times, UBS Says

Dec 13, 2024

11:57 AM EST, 12/13/2024 (MT Newswires) -- Eaton (ETN) has strong long-term growth prospects due to robust backlog growth and longer order lead times, UBS Securities said in a report emailed Friday. We think the company can sustain high single digit revenue growth for several years to come, driven by data center growth, electrification trends and reshoring of manufacturing capacity,...